Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections.

Autor: Kobayashi K; Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Japan Organization of Occupational Health and Safety, Chugoku Rosai Hospital, Hiroshima, Japan. Electronic address: kanaosandy@yahoo.co.jp., Takahashi S; Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Hokkaido, Japan., Yasuda M; Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Hokkaido, Japan., Miyazaki J; Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan., Wada K; Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan., Matsumoto M; Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, The University of Occupational and Environmental Health, Fukuoka, Japan., Hayami H; Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Hanafusa Urology Clinic(former), Miyazaki, Japan., Yamamoto S; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Hyogo, Japan., Kiyota H; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Iguchi Nephrourology and Internal Medicine Clinic Shinkoiwa, Tokyo, Japan., Sato J; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan., Matsumoto T; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan., Hasegawa N; The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan., Kobayashi I; Department of Infection Control and Prevention, Toho University Faculty of Nursing, Tokyo, Japan., Masumori N; Department of Urology, Sapporo Medical University School of Medicine, Hokkaido, Japan., Kimura T; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan., Yamada H; Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan., Nakagawa T; Department of Urology, Teikyo University School of Medicine, Tokyo, Japan., Kaneko T; Department of Urology, Teikyo University School of Medicine, Tokyo, Japan., Matsumoto K; Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan., Fujimura T; Department of Urology, Jichi Medical University, Tochigi, Japan., Kamei J; Department of Urology, Jichi Medical University, Tochigi, Japan., Ishikawa K; Department of Urology, School of Medicine, Fujita Health University, Aichi, Japan., Fujimoto K; Department of Urology, Nara Medical University, Nara, Japan., Nakai Y; Department of Urology, Nara Medical University, Nara, Japan., Shigemura K; Division of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan., Sadahira T; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Hinata N; Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan., Kitano H; Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan., Yamashita M; Department of Urology, Shinko Hospital, Hyogo, Japan., Yasufuku T; Department of Urology, Shinko Hospital, Hyogo, Japan., Komeda H; Department of Urology, Gifu Municipal Hospital, Gifu, Japan., Hiyama Y; Department of Urology, Hakodate Goryokaku Hospital, Hokkaido, Japan., Takahashi Y; Department of Urology, Gifu Prefectural General Medical Center, Gifu, Japan., Kanamaru S; Department of Urology, Kobe City Nishi-Kobe Medical Center, Hyogo, Japan., Murakami M; Department of Urology, Fuji City General Hospital, Shizuoka, Japan., Arakawa S; Department of Urology, Sanda City Hospital, Hyogo, Japan., Yamada D; Department of Urology, Mitoyo General Hospital, Kagawa, Japan., Mita K; Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital (formerly Hiroshima City Asa Citizens Hospital), Hiroshima, Japan., Hamasuna R; Department of Urology, Shin Kokura Hospital, Fukuoka, Japan., Tanaka K; Department of Urology, Kita-Harima Medical Center, Hyogo, Japan., Matsukawa M; Department of Urology, Takikawa Municipal Hospital, Hokkaido, Japan., Takaoka E; Department of Urology, International University of Health and Welfare Hospital, Tochigi, Japan., Shigeta M; Department of Urology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan., Takenaka T; Department of Urology, Japanese Red Cross Okayama Hospital, Okayama, Japan., Nishino M; Department of Urology, Japanese Red Cross Hamamatsu Hospital, Shizuoka, Japan., Ishitoya S; Department of Urology, Japanese Red Cross Otsu Hospital, Shiga, Japan., Hayakawa S; Department of Urology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan., Okumura K; Department of Urology, Tenri Hospital, Nara, Japan., Ueda M; Department of Urology, Tenri Hospital, Nara, Japan.
Jazyk: angličtina
Zdroj: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2024 Jul; Vol. 30 (7), pp. 579-589. Date of Electronic Publication: 2024 Apr 06.
DOI: 10.1016/j.jiac.2024.03.024
Abstrakt: Introduction: Antimicrobial susceptibility patterns of bacterial pathogens isolated from patients with complicated urinary tract infections were analyzed using the national surveillance data, comprising 793 bacterial strains from eight clinically relevant species.
Materials and Methods: Data were collected for the fourth national surveillance project from July 2020 to December 2021 by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Disease, and the Japanese Society of Clinical Microbiology. Surveillance was supervised with the cooperation of 43 medical institutions throughout Japan.
Results: Fluoroquinolone required a minimum inhibitory concentration (MIC) of 2-64 mg/L to inhibit the 330 tested Escherichia coli strains. The proportion of levofloxacin-resistant E. coli strains increased from 28.6% in 2008 to 29.6% in 2011, 38.5% in 2015, and 44.5% in 2021. The proportion of levofloxacin-resistant strains of Pseudomonas aeruginosa also increased from previous survey results, showing a continuing downward trend. Conversely, the proportion of levofloxacin-resistant strains of Enterococcus faecalis decreased relative to previous reports. Neither multidrug-resistant P. aeruginosa nor carbapenem-resistant Enterobacteriaceae were detected. For methicillin-resistant Staphylococcus aureus (MRSA), the proportion of vancomycin-susceptible strains (MIC of 2 μg/mL) decreased from 14.7% to 7.7%.
Discussion: Bacterial strains that produced extended-spectrum β-lactamase included E. coli (82/330 strains, 24.8%), Klebsiella pneumoniae (11/68 strains, 16.2%), and Proteus mirabilis (4/26 strains, 15.4%). As compared to previous surveillance reports, these strains showed an increase in proportion over the years.
Competing Interests: Declaration of competing interest Satoshi Takahashi received speaker honoraria from Fujirebio Inc. and research funding from Shino-Test Corporation, Roche Diagnostic K. K., Fujirebio Inc., and Abbott Japan Co., Ltd. Koichiro Wada received speaker honoraria from Janssen Pharmaceutical K.K., and MSD K.K. Shingo Yamamoto received speaker honoraria from MSD K.K., Fuso Pharmaceutical Industries, Ltd., Daiichi Sankyo Co., Ltd. and scholarship donations from Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd. and research funding from Takeda Pharmaceutical Co., Ltd. Tetsuya Matsumoto received speaker honoraria from MSD K.K., Pfizer Japan Inc., and Kyorin Pharmaceutical Co., Ltd., and research funding from Kewpie Corporation., Biofermin Pharmaceutical Co., Ltd. Kazumasa Matsumoto received research funding from Sysmex Corporation. Tohru Nakagawa received speaker honoraria from Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K.
(Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: